: Ethical > Circulatory System
: 1 tab. contains
atorvastatin calcium anhydrous......10.36 mg
(10 mg as atorvastatin)
atorvastatin calcium anhydrous......41.4 mg
(40 mg as atorvastatin)
1.reduce total-C, LDL-C, apo B, and TG levels and increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia 2.Fredrickson Type IV 3.Fredrickson Type III who do not respond adequately to diet 4.reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia 5.reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls(10-17 years of age) with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.
The patient should be placed on a standard cholesterol-lowering diet before receiving Atostar and should continue on this diet during treatment with Atostar.
1. Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)
The recommended starting dose of Atostar is 10 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 20 mg or 40 mg once daily.
The dosage range of Atostar is 10 to 80 mg once daily. Atostar can be administered as a single dose at any time of the day, with or without food.
2. Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age)
The recommended starting dose of Atostar is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population).
3. Homozygous Familial Hypercholesterolemia
The dosage of Atostar in patients with homozygous FH is 10 to 80 mg daily. Atostar should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
4. Dosage in Patients With Renal Insufficiency
Dosage adjustment in patients with renal dysfunction is not necessary.
5. Efficacy and safety in adults age 70 or older using recommended doses is similar to that seen in the general population.
4. Packing Size
: 30 T, 100 T
5. Related Disease
: Cardiovascular system